

## **Public Assessment Report**

### **Scientific discussion**

**Gaviscon Duo Muntsmaak  
250 mg/106.5 mg/187.5 mg, chewable tablets  
(sodium alginate, sodium hydrogen carbonate,  
calcium carbonate)**

**NL/H/5462/001/DC**

**Date: 5 March 2025**

This module reflects the scientific discussion for the approval of Gaviscon Duo Muntsmaak 250 mg/106.5 mg/187.5 mg, chewable tablets. The procedure was finalised on 2 August 2023. For information on changes after this date please refer to the 'steps taken after finalisation' at the end of this PAR.

## List of abbreviations

ASMF	Active Substance Master File
CEP	Certificate of Suitability to the monographs of the European Pharmacopoeia
CHMP	Committee for Medicinal Products for Human Use
CMD(h)	Coordination group for Mutual recognition and Decentralised procedure for human medicinal products
CMS	Concerned Member State
EDMF	European Drug Master File
EDQM	European Directorate for the Quality of Medicines
EEA	European Economic Area
EMA	European Medicines Agency
ERA	Environmental Risk Assessment
GERD	Gastro-oesophageal Reflux Disease
ICH	International Conference of Harmonisation
MAH	Marketing Authorisation Holder
NERD	Non-Erosive Reflux Disease
Ph.Eur.	European Pharmacopoeia
PL	Package Leaflet
PPI	Protein Pump Inhibitor
RH	Relative Humidity
RMP	Risk Management Plan
RMS	Reference Member State
SmPC	Summary of Product Characteristics
TSE	Transmissible Spongiform Encephalopathy

## I. INTRODUCTION

Based on the review of the quality, safety and efficacy data, the Member States have granted a marketing authorisation for Gaviscon Duo Muntsmak 250 mg/106.5 mg/187.5 mg, chewable tablets, from Reckitt Benckiser Healthcare B.V.

The product is indicated for: treatment of acid related symptoms of gastro-oesophageal reflux such as heartburn, acid regurgitation and indigestion, for example following meals or during pregnancy.

The product is indicated in adults and children aged 12 years and over.

A comprehensive description of the up-to-date indications and posology is given in the SmPC.

The marketing authorisation has been granted pursuant to Article 10a of Directive 2001/83/EC. This decentralised procedure concerns a bibliographical application based on well-established medicinal use of fixed combination medicinal products with sodium alginate, sodium hydrogen carbonate and calcium carbonate as active substances. For this type of application, the MAH needs to demonstrate that the active substance of the medicinal product has been in well-established medicinal use within the Community for at least 10 years in the specific therapeutic use. The results of non-clinical and clinical trials are replaced by detailed references to published scientific literature.

Fixed combination medicinal products with sodium alginate, sodium hydrogen carbonate, and calcium carbonate as active substances were first introduced into the European market at least ten years ago as a preoperative medication for treatment of acid related symptoms of gastro-oesophageal reflux such as heartburn, acid regurgitation and indigestion, for example following meals or during pregnancy.

The MAH submitted publications from medical literature and also clinical study reports on the effects of proposed chewable tablets containing sodium alginate, sodium hydrogen carbonate, and calcium carbonate in fixed combination. Additionally, the MAH submitted publications from medical literature and clinical study reports on medicinal products with different active substances and/or a different formulation (e.g. fixed dose combination liquids). However, publications from literature on tablets with sodium alginate, sodium hydrogen carbonate, and calcium carbonate in fixed combination will be primarily included in current assessment.

The concerned member states (CMS) involved in this procedure were Austria, Bulgaria, Denmark, Estonia, Finland, France, Hungary, Iceland, Latvia, Lithuania, Norway, Poland, Portugal and Romania.

## II. QUALITY ASPECTS

### II.1 Introduction

Gaviscon Duo Muntsmaak is a circular, bi-layer chewable tablet with bevelled edges. One layer of the chewable tablet is pink and slightly mottled with “GBD” surface markings and the other white with sword and circle surface markings.

The chewable tablet contains as active substance 250 mg sodium alginate, 106.5 mg sodium hydrogen carbonate and 187.5 mg calcium carbonate.

The excipients are: macrogol, mannitol (E421), copovidone, cranberry flavour (flavouring substance(s), arabic gum, potato maltodextrin, sucrose, glyceryl triacetate), raspberry flavour (flavouring substance(s), waxy maize maltodextrin, propylene glycol (E1520), modified waxy maize starch), fruit flavour (flavouring substance(s), arabic gum, potato maltodextrin, sucrose, glyceryl triacetate, propylene glycol (E1520)), acesulfame potassium, aspartame (E951), carmoisine lake (E122), magnesium stearate and xylitol DC (contains carmellose sodium).

The chewable tablets are packed in blisters of clear polyvinyl chloride/polyethylene/polyvinylidene chloride (PVC/PE/PVdC) laminated with aluminium foil lidding packed into cartons.

### II.2 Drug Substance

The active substances are sodium alginate (alginate), calcium carbonate (antacid) and sodium hydrogen carbonate (antacid). All three active substances are established and described in the European Pharmacopoeia (Ph.Eur.).

Sodium alginate is a white or pale yellowish-brown powder. It is slowly soluble in water forming a viscous colloidal solution and practically insoluble in ethanol (96%).

Calcium carbonate is a white or almost white powder. It is practically insoluble in water.

Sodium hydrogen carbonate is a white or almost white, crystalline powder. It is soluble in water and practically insoluble in ethanol (96%).

The CEP procedure is used for all three active substances. Under the official Certification Procedures of the EDQM of the Council of Europe, manufacturers or suppliers of substances for pharmaceutical use can apply for a certificate of suitability concerning the control of the chemical purity and microbiological quality of their substance according to the corresponding specific monograph, or the evaluation of reduction of Transmissible Spongiform Encephalopathy (TSE) risk, according to the general monograph, or both. This procedure is meant to ensure that the quality of substances is guaranteed and that these substances comply with the Ph.Eur.

### Manufacturing process

A CEP has been submitted for each active substance; therefore no details on the manufacturing process have been included.

### Quality control of drug substance

#### *Sodium alginate*

The active substance specification is considered adequate to control the quality and meets the requirements of the monograph in the Ph. Eur. The specification is acceptable in view of the route of synthesis and the various European guidelines. Batch analytical data demonstrating compliance with this specification have been provided for three batches.

#### *Calcium carbonate*

The active substance specification is considered adequate to control the quality and meets the requirements of the monograph in the Ph. Eur. and CEP. In view of the route of synthesis and the various European guidelines, the specification is acceptable. Batch analytical data demonstrating compliance with this specification have been provided for six batches.

#### *Sodium hydrogen carbonate*

The active substance specification is considered adequate to control the quality and meets the requirements of the monograph in the Ph. Eur. and CEP. In view of the route of synthesis and the various European guidelines, the specification is acceptable. Batch analytical data demonstrating compliance with this specification have been provided for three batches.

### Stability of drug substance

#### *Sodium alginate*

A retest period could be granted of 12 months when stored under the stated conditions.

#### *Calcium carbonate*

A retest period could be granted of 24 months from supplier 1 when stored under the stated conditions.

A retest period could be granted of 12 months from supplier 2 when stored under the stated conditions.

#### *Sodium hydrogen carbonate*

A retest period could be granted of 36 months when stored under the stated conditions.

## **II.3 Medicinal Product**

### Pharmaceutical development

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

A limited amount of information is available as the medicinal product formulation is based on a currently registered product Gaviscon Double Action Tablets Peppermint, with only a different flavouring component. A composition comparison is presented, and the pharmaceutical development is almost fully based on the marketed product. The information provided confirms that the proposed (conventional) manufacturing process is acceptable

using the proposed equipment settings and process controls. The MAH claims the efficacy of the finished product is achieved due to the acid neutralising capacity and raft-forming capability of the finished product. These parameters are therefore discussed and compared with the reference product. *In vitro* tests demonstrated similar antacid and raft-forming capacity of the reference and test products. The MAH investigated the palatability of the product and its impact on the patient compliance. Additionally, the size of the tablets is the same as the marketed Gaviscon Double Action Tablets Peppermint.

#### Manufacturing process

The product is manufactured using a standard process which consists of mixing, granulation and compression. The manufacturing process has been validated according to relevant European/ICH guidelines. Process validation data on the product have been presented for three batches in accordance with the relevant European guidelines.

#### Control of excipients

The excipients comply with the Ph. Eur. requirements or in-house specification. The compositions of the flavours is indicated. These specifications are acceptable.

#### Quality control of drug product

The finished product specifications are adequate to control the relevant parameters for the dosage form. The specification includes tests for form, shape, surface impression, colour, odour, identification of alginate, carbonate and calcium, content of alginate, bicarbonate, calcium and total carbon dioxide, water content, weight variation and microbial quality. Considering that the mode of action of the drug product is physical and no absorption, neither dissolution test nor disintegration tests are required. Limits in the specification have been justified and are considered appropriate for adequate quality control of the product. An adequate nitrosamines risk evaluation report has been provided. No risk for presence of nitrosamines in the drug product was identified.

Due to the source of the natural ingredients and manufacturing process of the active ingredients, a number of metallic ions are present as residues in very small amounts. The concentrations of heavy metals are controlled by specifications and are all well within normal dietary intakes and therefore do not present any additional toxicological hazard. The elemental impurities testing has been carried out on the finished formulation as per ICH Q3D guideline, and all the elemental impurities are found to be below the Permitted Daily Exposure (PDE) values.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data three production scale batches from the proposed production site have been provided, demonstrating compliance with the specification.

#### Stability of drug product

Stability data on the product have been provided for three batches stored at 25°C/ 60% RH (104 weeks) and 40°C/75% RH (26 weeks) in accordance with applicable European guidelines. Photostability results demonstrated that the product is chemically and physically stable up to one week. On basis of the data submitted, a shelf life was granted of 24 months. The labelled

storage conditions are “Do not store above 30°C. Store in the original package in order to protect from moisture.”

#### Specific measures concerning the prevention of the transmission of animal spongiform encephalopathies

There are no substances of ruminant animal origin present in the product nor have any been used in the manufacturing of this product, so a theoretical risk of transmitting TSE can be excluded.

### **II.4 Discussion on chemical, pharmaceutical and biological aspects**

Based on the submitted dossier, the member states consider that Gaviscon Duo Muntsmaak has a proven chemical-pharmaceutical quality. Sufficient controls have been laid down for the active substance and finished product.

No post-approval commitments were made.

## **III. NON-CLINICAL ASPECTS**

### **III.1 Pharmacology**

Sodium alginate acts to impede gastro-oesophageal reflux by the formation of an alginate raft that floats on the surface of the stomach contents. The bicarbonate, from the sodium bicarbonate, reacts with gastric acid forming carbon dioxide, which becomes entrapped in the gel and provides it with buoyancy. More recent *in vitro* studies revealed that sodium alginate adheres to the oesophageal mucosa, which suggests that sodium alginate may have a direct mucosal protective effect in addition to reducing reflux. There appears to be no evidence from animal models of the effect of sodium alginate on gastro-oesophageal reflux; however, the human clinical data are substantial.

A series of published animal studies have revealed that oral sodium alginate protects against experimentally-induced intestinal inflammation. It was demonstrated that, in acetic acid-induced colitis in rats, both pre-treatment and delayed treatment with 0.5% sodium alginate significantly reduced ( $p < 0.05$ ) the macroscopic scores of inflammation and ulceration. It also significantly reduced ( $p < 0.05$ ) the elevated serum and colonic tissue levels of proinflammatory cytokines (Mirshafiey et al, 2005).

*In vitro* experiments with a fibrosarcoma cell-line (WEHI-164) were also described that indicate that sodium alginate has a cell-stabilising effect, which is associated with reduced activity of the matrix metalloproteinases that are involved in epithelial inflammation and tissue destruction (Mirshafiey et al, 2005).

Sodium bicarbonate is a naturally occurring inorganic compound readily dissociating in water to sodium and bicarbonate ions, both normal constituents of vertebrate physiology; the principal extracellular buffer in the blood and interstitial fluid is the bicarbonate buffer system (OECD, 2002). In the case of the current orally administered products, sodium bicarbonate acts as an effervescent agent/gas forming agent active in the formation of the alginate raft

systems. When given orally both sodium and potassium hydrogen carbonate neutralise hydrochloric acid in gastrointestinal tract secretions with the production of carbon dioxide. They are used in the symptomatic management of gastrointestinal disorders associated with hyperacidity such as dyspepsia, gastro-oesophageal reflux disease and peptic ulcer disease (Martindale, 2017a).

Calcium carbonate can be used therapeutically as an antacid, a phosphate-binder in the treatment of hyperphosphataemia in patients with chronic renal failure and a calcium supplement in deficiency states and as an adjunct to treatment for osteoporosis (Martindale, 2017b). Doses of calcium carbonate administered orally include up to 1.5 g as an antacid (often in combination with other antacids), 3 to 7 g daily in the treatment of hyperphosphataemia, and 1 to 3 g daily as a calcium supplement (Martindale, 2017b).

### III.2 Pharmacokinetics

A study using <sup>14</sup>C-labelled alginate fed as 10% of the diet rats demonstrated that 85 - 91% of the radioactivity was recovered in the faeces, 0.11 - 0.16% in the urine, 0.21-0.42% in respiratory carbon dioxide and 0.002-0.007% in the plasma after 17 hours (Humphreys and Triffitt, 1968). The authors concluded that their data indicated a negligible degree of absorption of alginate following oral intake and assumed that the small amount of unrecovered alginate was due to experimental losses.

On oral administration of bicarbonate salts, such as sodium bicarbonate, any bicarbonate ions not involved in neutralisation of gastrointestinal acid (with the production of carbon dioxide) are absorbed. In the absence of a deficit of bicarbonate in the plasma, bicarbonate ions are readily excreted in the urine which is rendered alkaline (Martindale, 2017a). Excess sodium ions are readily excreted in the urine (OECD, 2002).

Calcium carbonate is converted to calcium chloride by gastric acid. Some of the calcium is absorbed from the intestines, via active transport or passive diffusion, but a large proportion (up to 80%) is reconverted to calcium carbonate and other insoluble calcium salts which are excreted in the faeces. Average absorption of calcium from calcium carbonate over a range of studies has been shown to be in the range of 20 to 40% with any unabsorbed portion excreted in the faeces (EFSA, 2011; Martindale, 2014). After intestinal absorption, calcium and carbonate/bicarbonate ions enter normal metabolic pathways and body pools; the majority of absorbed calcium is stored in the skeleton. Excess calcium is excreted with water via the kidneys (and also faeces and skin) and excess carbonate is excreted as carbon dioxide via respiration (EFSA 2011).

### III.3 Toxicology

Nonclinical data indicates that no toxicity should be expected from the quantities of sodium alginate administered in the recommended doses of the product. In addition, administration of sodium alginate has revealed no evidence of any potential for carcinogenic, mutagenic or reproductive toxicity (Til et al, 1986; Ishidate et al, 1984; Adaniya et al, 1993). There is some evidence of minor nephrotoxicity occurring after prolonged exposure to extremely high concentrations (25% of the diet) of sodium alginate in mice (Til et al, 1986), but this is not

relevant to the proposed clinical use. The widespread exposure of the human population to sodium alginate in both pharmaceutical and food products together with long-term post-marketing experience of Gaviscon formulations demonstrate that the products present little or no risk to human safety.

Sodium bicarbonate is generally regarded as a relatively non-toxic and non-irritant material when used at an appropriate dose. As with sodium salts in general adverse effects are attributable to electrolyte imbalances from excessive sodium. This risk is addressed by inclusion of the appropriate precautions and warnings in the prescribing information and labelling of the products. Although the few available non-clinical studies are not 'state of the art', a review of the published non-clinical data indicates that no toxicity should be expected from the quantities of sodium bicarbonate administered in the recommended dose of the products (OECD 2002). In addition, administration of sodium bicarbonate has revealed no evidence of any potential for carcinogenic, mutagenic or reproductive toxicity.

In the absence of any formal programme of non-clinical studies, the status of sodium bicarbonate, and sodium and bicarbonate ions, as naturally occurring inorganic constituents of vertebrate physiology together with the widespread exposure of the human population to sodium bicarbonate in both pharmaceutical and food products and the long-term post-marketing experience of Gaviscon formulations demonstrate that the product presents little or no risk to human safety.

Calcium carbonate is generally regarded as a relatively non-toxic and non-irritant material when used at an appropriate dose. The available toxicological database on calcium carbonate is limited, but does not give rise to concern, including the results of recent OECD and GLP compliant studies on nanoparticulate material. The few effects seen in studies in animals and humans are associated with high calcium carbonate intakes, and are also seen with other calcium salts (EFSA, 2011). In the absence of any evidence of major toxicity in non-clinical studies, the status of calcium and carbonate ions, as naturally occurring inorganic constituents of vertebrate physiology together with the widespread exposure of the human population to calcium carbonate in both pharmaceutical and food products and the long-term post-marketing experience of calcium carbonate containing formulations demonstrate that the product presents little or no risk to human safety.

The excipients in the Gaviscon tablet products are well-established pharmaceutical excipients and food additives and should present little risk to the general patient population. Appropriate precautions and warnings regarding patient groups more likely to experience adverse events are provided in the prescribing information and labelling of the products. In addition, no toxicological hazard is anticipated from the presence of trace levels of formaldehyde and metallic ions present in the sodium alginate used in the products.

During the production of the grade of sodium alginate used in Gaviscon products, formaldehyde is added as a preservative. Formaldehyde is a natural component present in all mammalian cells, humans have detectable quantities of natural formaldehyde in their circulation (about 2.5 mg/ml of blood), and it is rapidly detoxified by active enzymatic pathways. Use in man has been long-term and widespread with medical, industrial and food processing applications. According to the EFSA formaldehyde is toxic. For the Gaviscon

products, no toxicological hazard would be expected from the presence of formaldehyde residues as formaldehyde is present in the finished product at a concentration significantly below (over 100-fold lower) the tolerable intake of 5.2 mg/day established by the WHO for formaldehyde in drinking water (WHO, 2011).

### **III.4 Ecotoxicity/environmental risk assessment (ERA)**

Since Gaviscon Duo Muntsmaak is intended for generic substitution, this will not lead to an increased exposure to the environment. An environmental risk assessment was therefore not deemed necessary.

### **III.5 Discussion on the non-clinical aspects**

This product has been granted a market authorisation for well-established use. A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology data. Therefore, the member states agreed that no further non-clinical studies are required.

## **IV. CLINICAL ASPECTS**

### **IV.1 Introduction**

Gaviscon Duo Muntsmaak is a well-known active substance with established efficacy and tolerability. A clinical overview has been provided, which is based on scientific literature. The overview justifies why there is no need to generate additional clinical data. Therefore, the member states agreed that no further clinical studies are required.

### **IV.2 Pharmacokinetics**

It is acknowledged that systemic absorption of sodium alginate, sodium hydrogen carbonate, and calcium carbonate is limited and therefore of limited or no clinical relevance.

Alginate preparations do not possess any pharmacology in the true sense since their mode of action in prevention of reflux is physical. After emptying from the stomach, the formed alginate raft disintegrates as it passes through the remainder of the gastrointestinal tract and the components are excreted in the faeces. Although some absorption of components may occur, all of the components are well-known pharmaceutical or food ingredients and no safety issues would be expected in the general patient population. The MAH has not submitted publications on the pharmacokinetic effects of its proposed alginate-antacid formulation and currently authorized alginate-antacid formulations.

### **IV.3 Pharmacodynamics**

### Mechanism of action

The mode of action of medicinal products containing sodium alginate, sodium hydrogen carbonate and calcium carbonate is physical and does not depend on absorption into the systemic circulation.

In the acidic environment of the stomach alginate salts and alginic acids precipitate to form a low density, viscous gel (Knight et al, 1988; May et al, 1984). Sodium alginate is not absorbed systemically but forms a raft within the stomach.

The sodium hydrogen carbonate in the formulation reacts with the gastric acid to produce carbon dioxide, which becomes entrapped in the raft, increasing its buoyancy, so that the alginate gel floats on top of the stomach contents (Johnson et al, 1997; Johnson et al, 1998). Hence, the mode of action of sodium hydrogen carbonate in acid neutralization is essential for effective raft formation. Sodium hydrogen carbonate relieves heartburn and acid indigestion.

Calcium salts increase raft strength by formation of calcium ion cross-linkages between the alginate chains (Grant et al, 1973; Davies et al, 1994; Malmud et al, 1979). Calcium carbonate is an antacid that provides relief for heartburn, acid indigestion, and upset stomach. Calcium carbonate is also a dietary supplement that helps to provide calcium to support healthy bones, muscles, nervous system, and heart. Sodium hydrogen carbonate is an effective antacid that neutralizes gastric acid.

Taking things together, the combination of active substances provides a protective and neutralising effect: The protective effective is that on ingestion, the medicinal product reacts rapidly with gastric acid to form a protective barrier (raft) of alginic acid gel having a near neutral pH and which floats on the stomach contents. Effective impediment of gastro-oesophageal reflux may last for up to 4 hours. This means that acid regurgitation is mechanically prevented and the oesophagus is thus protected. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect (Mandel et al, 2000).

The neutralising effect is that calcium carbonate and sodium hydrogen carbonate react immediately following ingestion to neutralise gastric acid and provide fast relief from indigestion and heartburn. The total neutralising capacity of the product at the lowest dose of two tablets is approximately 10 mEqH<sup>+</sup>. This effect has also been demonstrated *in vivo* via intragastric pH monitoring using a multi-electrode catheter in fasted healthy male and female participants to remove variability caused by postprandial buffering (Wilkinson, 2018). In the study the primary endpoint was the percentage of time that intragastric pH  $\geq 4$  during the 30 minutes post-treatment period and the results recorded 50.8% of the time with Gaviscon Double Action versus 3.5% with placebo (p = 0.0051).

The medicinal product also neutralizes the postprandial acid pocket.

### Pharmacodynamic interactions with other medicinal products or substances

Due to the presence of calcium carbonate which acts as an antacid, a time-interval of 2 hours should be considered between intake of Gaviscon products and the administration of other

medicinal products, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates, and estramustine.

#### Genetic, age related and ethnic differences in PD response

Alginate, bicarbonate, calcium carbonate combinations have a non-systemic raft forming mode of action which is localized to the stomach. A key feature being an acidic environment is present from approximately 2 years, across difference ethnologies and is maintained during the aging process. Therefore, the raft forming capabilities are maintained and the efficacy of the product can be extrapolated across subpopulations.

#### Discussion and conclusion on pharmacodynamics

Gaviscon Duo Muntsmaak chewable tablets concern a fixed combination product with sodium alginate, sodium hydrogen carbonate, and calcium carbonate as active substances. According to literature, a fixed combination product with these active substances exerts both raft-forming (sodium alginate) and acid-neutralizing pharmacodynamic effects (sodium hydrogen carbonate, calcium carbonate).

In the submitted documentation on quality aspects of the proposed product and other alginate-antacid medicinal products registered in the European Union for more than 10 years, the MAH appropriately justified that the physicochemical, raft-forming, and acid-neutralizing properties of these products are similar. Based on this and minimal systemic availability of alginate-antacid it is concluded that pharmacodynamic effects of Gaviscon Duo Muntsmaak chewable tablets are similar to those of other alginate-antacid tablet formulations registered in the European Union for more than 10 years.

## **IV.4 Clinical efficacy**

1

The clinical efficacy of Gaviscon Double Action (DA) tablets at dosages of four times daily, two or four tablets during 7 days for symptomatic treatment of gastroesophageal reflux disease (GERD), was demonstrated in submitted publications (Thomas et al, 2014; Wilkinson et al, 2018). Referenced systematic review and meta-analysis by Leiman et al. (2016) and Tran et al. (2007), and the meta-analyses conducted by the MAH also support the efficacy of alginate-based treatments with respect to decreasing and resolving GERD symptoms. These meta-analyses included different alginate medicinal products and different formulations (e.g. tablets and liquid).

The posology for Gaviscon DA mixed berries tablets for gastro-oesophageal reflux of up to four times daily two to four tablets up to 7 days is in line with the posology of the decentralised registered Gaviscon DA chewable tablets (NL/H/4534/001) (2010) for a similar indication. Respective tablets were registered on a well-established use legal basis.

The MAH did not discuss to what extent literature on the clinical effects of Gaviscon DA tablets registered within the European Union for more than 10 years can be extrapolated to its proposed Gaviscon DA mixed berries chewable tablets. However, in submitted documentation on quality aspects the MAH appropriately justified that the physicochemical, raft-forming, and

---

1

acid-neutralizing properties of these products are similar. Because of this, the RMS is of the opinion that bridging of clinical effects reported for Gaviscon DA tablets in literature and proposed Gaviscon DA mixed berries chewable tablets is appropriate.

Aforementioned data support the clinical efficacy of Gaviscon DA mixed berries tablets for the treatment of acid related symptoms of gastro-oesophageal reflux such as heartburn, acid regurgitation and indigestion, for example following meals or during pregnancy in patients aged 12 years and above.

#### **IV.5 Clinical safety**

Fixed dose combination products of sodium alginate, sodium hydrogen carbonate, and calcium carbonate with varying amounts of active substances and in different formulations (tablets, suspensions) are used frequently in European clinical practice for more than a decade. Submitted publications and PSUR data show that the risk of adverse events is overall low, i.e. <1% per year (Hampson et al, 2010; Thomas et al, 2014; Coyle et al, 2017; Wilkinson et al, 2018). Most of the reported adverse events were non-serious. Reported adverse events can be treated if necessary. Hence, fixed dose combination products of sodium alginate, sodium hydrogen carbonate, and calcium carbonate are well-tolerated by the majority of patients.

Since the efficacy of Gaviscon DA tablets with respect to the treatment of acid related symptoms of gastro-oesophageal reflux such as heartburn, acid regurgitation and indigestion can be extrapolated to proposed Gaviscon DA mixed berries chewable tablets, this will also apply to the clinical safety of these medicinal products.

There is no evidence to suggest that the usual adult dosage needs to be modified for use in elderly patients.

Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.

Very rarely (less than one in 10,000) patients may develop allergic manifestations such as urticaria, anaphylactic and anaphylactoid reactions. The only proposed contraindication to use of Gaviscon DA is known or suspected hypersensitivity to any of the active substances or to any of the excipients (e.g. carmoisine lake).

Gaviscon DA liquid and tablets contain sodium ions, but the levels present are not considered sufficient to require contraindication of its use in any patient group, although this should be taken into account when a highly restricted salt diet is recommended such as in some cases of congestive cardiac failure and renal impairment.

Due to the presence of calcium, care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.

The tablets contain aspartame and should not be taken by patients with phenylketonuria.

Due to the physical mode of action of Gaviscon DA tablets and liquid formulations, these formulations may be used during pregnancy and lactation.

Patients should seek medical advice if symptoms do not improve after seven days. Since in rare cases the symptoms associated with gastric reflux may result from a more serious underlying condition such as gastric carcinoma, this is a sensible measure to guard against prolonged self-medication resulting in such conditions going undiagnosed.

#### IV.6 Risk Management Plan

The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Gaviscon Duo Muntsmaak.

**Table 1. Summary table of safety concerns as approved in RMP**

Important identified risks	None.
Important potential risks	None.
Missing information	None.

The member states agreed that routine pharmacovigilance activities and routine risk minimisation measures are sufficient for the risks and areas of missing information.

#### IV.7 Discussion on the clinical aspects

For this authorisation, reference is made to the clinical studies and experience with fixed dose combinations of sodium alginate, sodium hydrogen carbonate, and calcium carbonate. No new clinical studies were conducted. The MAH demonstrated that the use of fixed dose combinations is well-established within the European Union.

The clinical efficacy at an acceptable safety level was demonstrated for such fixed dose combinations for treatment of acid related symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion.

Risk management is adequately addressed. The clinical aspects of this product are approvable.

## V. USER CONSULTATION

The package leaflet (PL) has been evaluated via a user consultation study in accordance with the requirements of Articles 59(3) and 61(1) of Directive 2001/83/EC.

A user consultation with target patient groups on the package leaflet (PL) has been performed on the basis of a bridging report making reference to Gaviscon Double Action Tablets, NL/H/4534/001. The bridging report submitted by the MAH has been found acceptable; bridging is justified for both content and layout of the leaflet.

## VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

Gaviscon Duo Muntsmaak 250 mg/106.5 mg/187.5 mg, chewable tablets has a proven chemical-pharmaceutical quality and is a well-known medicinal product with an established favourable efficacy and safety profile.

Bioequivalence has been shown to be in compliance with the requirements of European guidance documents.

The Board followed the advice of the assessors.

There was no discussion in the CMD(h). Agreement between member states was reached during a written procedure. The member states, on the basis of the data submitted, considered that essential similarity has been demonstrated for Gaviscon Duo Muntsmaak with the reference product, and have therefore granted a marketing authorisation. The decentralised procedure was finalised with a positive outcome on 2 August 2023.

## LITERATURE REFERENCES

Adaniya, G. K., Rawlins, R. G., Quigg, J. M., Roblero, L., Miller, I. F., & Zaneveld, L. J. (1993). First pregnancies and livebirths from transfer of sodium alginate encapsulated embryos in a rodent model. *Fertility and sterility*, *59*(3), 652-656.

Coyle, C, Crawford, G, Wilkinson, J, Thomas, S. J, & Bytzer, P. (2017). Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. *Alimentary Pharmacology & Therapeutics*, *45*(12), 1524-1533.

Davies, N. M, Farr, S. J, Kellaway, I. W, Taylor, G, & Thomas, M. (1994). A comparison of the gastric retention of alginate containing tablet formulations with and without the inclusion of excipient calcium ions. *International journal of pharmaceutics*, *105*(2), 97-101.

EFSA. 2011. "Scientific Opinion on re-evaluation of calcium carbonate (E 170) as a food additive." *EFSA Journal* *9* (7):n/a-n/a. doi: 10.2903/j.efsa.2011.2318.

EFSA. 2014. "Scientific Opinion on the safety and efficacy of formaldehyde for all animal species based on a dossier submitted by Adiveter S.L." *EFSA Journal* *12* (2). doi:10.2903/j.efsa.2014.3562.

Grant, G. T, Morris, E. R, Rees, D. A, Smith, P. J, & Thom, D. (1973). Biological interactions between polysaccharides and divalent cations: the egg-box model. *FEBS letters*, *32*(1), 195-198.

Hampson, F. C, Jolliffe, I. G, Bakhtyari, A, Taylor, G, Sykes, J, Johnstone, L. M, & Dettmar, P. W. (2010). Alginate-antacid combinations: raft formation and gastric retention studies. *Drug development and industrial pharmacy*, *36*(5), 614-623.

Humphreys, E. R, & Triffitt, J. T. (1968). Absorption by the rat of alginate labelled with carbon-14. *Nature*, *219*(5159), 1172-1173.

Ishidate Jr, M., Sofuni, T., Yoshikawa, K., Hayashi, M., Nohmi, T., Sawada, M., & Matsuoka, A. (1984). Primary mutagenicity screening of food additives currently used in Japan. *Food and chemical toxicology*, *22*(8), 623-636.

Johnson, F. A, Craig, D. Q. M, Mercer, A. D, & Chauhan, S. (1997). The effects of alginate molecular structure and formulation variables on the physical characteristics of alginate raft systems. *International Journal of Pharmaceutics*, *159*(1), 35-42.

Johnson, F. A, Craig, D. Q. M, Mercer, A, & Chauhan, S. (1998). The use of image analysis as a means of monitoring bubble formation in alginate rafts. *International journal of pharmaceutics*, *170*(2), 179-185.

Knight, L. C, Maurer, A. H, Ammar, I. A, Siegel, J. A, Fisher, R. S, & Malmud, L. S. (1988). Use of <sup>111</sup>In-labeled alginate to study the pH dependence of alginic acid anti-esophageal reflux

barrier. *International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology*, 15(5), 563-571.

Leiman, D. A, Riff, B. P, Morgan, S, Metz, D. C, Falk, G. W, French, B, ... & Lewis, J. D. (2017). Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. *Diseases of the Esophagus*, 30(5), 1.

Mandel, Daggy, Brodie, & Jacoby. (2000). alginate-raft formulations in the treatment of heartburn and acid reflux. *Alimentary pharmacology & therapeutics*, 14(6), 669-690.

Malmud, L. S, Charkes, N. D, Littlefield, J, Reilley, J, Stern, H, Rosenberg, R, & Fisher, R. S. (1979). The mode of action of alginic acid compound in the reduction of gastroesophageal reflux. *Journal of Nuclear Medicine*, 20(10), 1023-1028.

Martindale. 2014. Calcium. In *Martindale: The Complete Drug Reference. Medicines Complete*.

Martindale. 2017a. Bicarbonate. In *Martindale: The Complete Drug Reference. Medicines Complete*.

Martindale. 2017b. Calcium carbonate. In *Martindale: The Complete Drug Reference. Medicines Complete*.

May, H. A, Wilson, C. G, & Hardy, J. G. (1984). Monitoring radiolabelled antacid preparations in the stomach. *International journal of pharmaceutics*, 19(2), 169-176.

Mirshafiey, A, Khodadadi, A, Rehm, B. H, Khorramizadeh, M. R, Eslami, M. B, Razavi, A, & Saadat, F. (2005). Sodium alginate as a novel therapeutic option in experimental colitis. *Scandinavian journal of immunology*, 61(4), 316-321.

OECD. 2002. Sodium bicarbonate, CAS N°: 144-55-8. In *Screening Information Dataset (SIDS) Initial Assessment Profile (SIAP)*: Organisation for Economic Co-operation and Development (OECD)

Thomas, E, Wade, A, Crawford, G, Jenner, B, Levinson, N, & Wilkinson, J. (2014). Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action)—a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. *Alimentary pharmacology & therapeutics*, 39(6), 595-602.

Til, H. P., Feron, V. J., Immel, H. R., & Vogel, W. F. (1986). Chronic (89-week) feeding study with hydroxypropyl distarch phosphate, starch acetate, lactose and sodium alginate in mice. *Food and chemical toxicology*, 24(8), 825-834.

Tran, T, Lowry, A. M, & El-Serag, H. B. (2007). Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. *Alimentary pharmacology & therapeutics*, 25(2), 143-153.

WHO. 2005. Formaldehyde in Drinking-water; Background document for development of WHO Guidelines for Drinking-water Quality (WHO/SDE/WSH/05.08/48). WHO.

WHO. 2011. "Chromium." In *Guidelines for drinking-water quality*, 340. WHO.

Wilkinson, J, Abd-Elaziz, K, den Daas, I, Wemer, J, van Haastert, M, Hodgkinson, V, ... & Coyle, C. (2018). Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate antacid formulation (Gaviscon Double Action). *Drug development and industrial pharmacy*, 45(3), 430-438.

## STEPS TAKEN AFTER THE FINALISATION OF THE INITIAL PROCEDURE - SUMMARY

Procedure number	Scope	Product Information affected	Date of end of procedure	Approval/ non approval	Summary/ Justification for refuse
NL/H/5462/IB/001/G	Change in the (invented) name of the medicinal product - for Nationally Authorised Products + Changes in the composition (excipients) of the finished product - Changes in components of the flavouring or colouring system	Yes	12 July 2024	Not approved.	Proposed name for Norway was not accepted.
NL/H/5462/IB/002/G	Change in the (invented) name of the medicinal product - for Nationally Authorised Products + Changes in the composition (excipients) of the finished product - Changes in components of the flavouring or colouring system	Yes	6 December 2024	Approved	N.A.
NL/H/5462/001/IA/003	Change in the manufacturing process of the finished product , including an intermediate used in the manufacture of the finished product -	No	11 November 2024	Approved	N.A.

	Minor change in the manufacturing process.				